MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

DURHAM,  NC,  and  LIEGE,  BELGIUM -  November  29, 2010 -  MDxHealth  SA  (NYSE
Euronext:  MDXH),  a  leading  molecular  diagnostics  company  in  the field of
personalized  cancer  treatment,  today  announced  that  it  has granted a non-
exclusive  worldwide  license  for  its  patented methylation specific PCR (MSP)
technology to Takara Bio Inc. (Tokyo Stock Exchange: 4974.T).
 
Under  the  agreement,  Takara  Bio  Inc.  (Takara)  has  licensed  the  use  of
MDxHealth's  MSP technology, the most widely applied methylation technology, for
the  scientific research  market in  exchange for  an upfront fee plus royalties
from future sales utilizing this technology. Other terms were not disclosed.
 
Takara  is  an  emerging  global  player  in  the  market for research reagents,
scientific  instruments  and  contract  research  services based on cutting edge
genetic  engineering technologies.  Takara's advanced  capabilities increasingly
also focus on DNA methylation.
 
About MDxHealth
 
MDxHealth   is  a  leading  molecular  diagnostics  company  that  develops  and
commercializes  oncology-based  molecular  diagnostic  testing  for personalized
medicine.  The company's tests are based on patented gene methylation technology
and  assist physicians  with the  diagnosis of  cancer, prognosis  of recurrence
risk,  and prediction of response to  a specific therapy. MDxHealth collaborates
with  leading  cancer  research  center  such  as Johns Hopkins University, Duke
University,  Lovelace Respiratory  Research Institute,  Eastern Virginia Medical
School,  Cleveland Clinic, Memorial Sloan Kettering, and major European academic
medical  centers.  The  company  has  a  number  of commercial and collaborative
partnerships   with   LabCorp,  Merck  &  Co./Schering  Plough,  GlaxoSmithKline
Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.
 
About Takara Bio Inc.
 
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As
world leader in biotechnology research and development, Takara Bio was the first
company  to market  PCR technology  in Japan  and is  also the  developer of the
RetroNectin®  reagent, which is  a world standard  in gene therapy protocols. In
addition  to  providing  research  reagents  and  equipment  to the life science
research  market,  Takara  Bio  has  active  research  and  product  development
activities  in  the  fields  of  gene  and  cell-based therapy, and agricultural
biotechnology;  and is committed to preventing  disease and improving quality of
life  for  all  people  through  the  use  of  biotechnology.  Through strategic
alliances  with other  industry leaders,  the Company  aims to  extend its reach
around the world. More information is available at http://www.takara.com.
 
For more information:
 
Dr. Jan Groen, CEO                             Hans Herklots
 
MDxHealth                                           Capricorn One
 
+32 4 364 20 70                                   +41 79 598 7149
 
This  press  release  contains  forward-looking  statements  and  estimates with
respect  to the  anticipated future  performance of  MDxHealth and the market in
which  it operates. Such  statements and estimates  are based on assumptions and
assessments  of known and unknown risks,  uncertainties and other factors, which
were  deemed  reasonable  but  may  not  prove  to be correct. Actual events are
difficult  to predict,  may depend  upon factors  that are  beyond the Company's
control,  and  may  turn  out  to  be  materially different. MDxHealth expressly
disclaims  any obligation to update any  such forward-looking statements in this
release  to reflect any  change in its  expectations with regard  thereto or any
change  in events,  conditions or  circumstances on  which any such statement is
based unless required by law or regulation
 
[HUG#1466101]
 
2010-11-29: 
http://hugin.info/137314/R/1466101/404047.pdf
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: MdxHealth via Thomson Reuters ONE